达比加群对门静脉血栓再通率、疾病进展及生存期的经验
研究评估达比加群治疗非肿瘤性急性及慢加急性门静脉血栓的临床、促凝及遗传风险因素与结局。119例患者接受达比加群,中位随访32个月再通率47.1%,高于未抗凝组自发性再通率21.4%(p=0.005),VKA组无再通。高FVIII:Ag为非再通预测因素,达比加群在Child-Pugh A/B级肝硬化中安全,CP-C级需进一步研究。
要点
- 达比加群组总体再通率47.1%,未抗凝组自发性再通率21.4%(p=0.005),VKA组无再通。
- 多变量分析显示FVIII:Ag水平(HR 0.6)、非闭塞性PVT(HR 3.5)和急性PVT(HR 2.1)为再通预测因素。
- 达比加群在Child-Pugh A和B级肝硬化中安全,CP-C级需进一步研究。
核心结论
- 达比加群治疗119例门静脉血栓患者,32个月随访中47%实现再通,高于未治疗队列的自发性再通率21.4%。
- 高FVIII:Ag水平是非再通的预测因素。
- 达比加群在Child-Pugh A和B级肝硬化中安全,在CP-C级需进一步研究。
研究设计与样本
- 研究纳入2021年1月至2024年1月新诊断的非肿瘤性急性及慢加急性门静脉血栓患者(年龄≥18岁),无肝硬化或肝硬化Child-Pugh A/B/C≤10分者开始达比加群治疗并随访。
- 达比加群组119例,对照组包括28例拒绝抗凝或无法随访者及6例CP-C级接受VKA者。
主要发现
- 达比加群组PVT类型1为61例(51.3%)、类型2为34例(28.6%)、类型3为24例(20.2%);肝硬化72例(60.5%),其中CP-A 27例(37.5%)、CP-B 43例(59.7%)、CP-C 2例(2.8%)。
- 促凝因素包括JAK2V617F突变(10.1%)、CALR突变(2.5%)、因子V Leiden突变(1.6%)、抗磷脂综合征(15.2%)、孤立性蛋白C缺乏(14.3%)和蛋白S缺乏(16.8%)。
- 达比加群组总体再通率56例(47.1%),其中完全再通25例(21%)、部分再通31例(26%)、PVT稳定63例(52.9%),中位随访32个月。
- 未抗凝组自发性再通率21.4%(28例;与达比加群组相比p=0.005),VKA组无再通。
- 多变量分析显示再通预测因素为FVIII:Ag水平(HR 0.6;95%CI 0.3-0.9,p=0.032)、非闭塞性PVT(HR 3.5;95%CI 1.9-5.6,p=0.025)和急性PVT(HR 2.1;95%CI 1.5-3.2,p=0.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: We assessed clinical, procoagulant and genetic risk factors and clinical outcomes in dabigatran-treated patients with non-tumoural acute and acute-on-chronic portal vein thrombosis (PVT). METHODS: Patients with a new diagnosis of non-tumoural acute and acute-on-chronic PVT between January 2021 and January 2024 (aged ≥ 18 years) in those without/with cirrhosis (Child-Pugh (CP)-A/B/C ≤ 10) were started on dabigatran and followed and compared with those on vitamin K antagonist (VKA) and untreated individuals. RESULTS: Dabigatran was prescribed in 119 patients with PVT type 1 (61, 51.3%), type 2 (34, 28.6%), type 3 (24, 20.2%); 72 (60.5%) with cirrhosis [CP-A (27, 37.5%), CP-B (43, 59.7%) and CP-C10 (2, 2.8%)]. Procoagulant factors noted were JAK2V617F (10.1%), CALR (2.5%) and factor V Leiden (1.6%) mutations, antiphospholipid syndrome (APS, 15.2%), isolated Protein C (14.3%) and Protein S (16.8%) deficiency. COMPARATORS: 28 patients who declined anticoagulation/were unable to come for follow-up, and six with CP-C received VKA. Overall recanalization rate (RR) on dabigatran was 56 (47.1%); 25 (21%) complete recanalization, 31 (26%) partial recanalization and 63 (52.9%) stable PVT over median follow-up of 32 months. Patients not anticoagulated had a spontaneous RR in 21.4% (28 patients; p = 0.005 compared with dabigatran group) and none recanalized on VKA. On multivariable analysis, predictors of recanalization on dabigatran were Factor VIII Antigen level (FVIII:Ag, HR 0.6; 95% CI 0.3-0.9, p = 0.032), non-occlusive PVT (HR 3.5, 95% CI 1.9-5.6, p = 0.025) and acute PVT (HR 2.1; 95% CI 1.5-3.2, p = 0.003). Mortality was 14 (11.8%). CONCLUSION: On dabigatran, 47% of 119 patients achieved portal vein recanalization over 32 months of follow-up which was higher than the spontaneous RR (21.4%) in an untreated cohort. High Factor VIII:Ag was a predictor of non-recanalization. Dabigatran was safe in cirrhosis (CP-A and B) while further work is needed in CP-C.
引用
- Premkumar M, Bhujade H, Sharma P, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025. PMID: 39748673. doi:10.1111/apt.18474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。